The Corporation focussed on the Biology of Healing recently presented an indepth update on its two flagship programs, Plasminogen (plasma derived) and PBI-4050 (small molecule), as well as on operations as it prepares to become a commercial producer of plasma derived proteins ahead of next years’ anticipated Plasminogen launch.
06 Dec 2016
Scaling up
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Scaling up
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
06 Dec 2016 -
Author:
Derren Nathan -
Pages:
14
The Corporation focussed on the Biology of Healing recently presented an indepth update on its two flagship programs, Plasminogen (plasma derived) and PBI-4050 (small molecule), as well as on operations as it prepares to become a commercial producer of plasma derived proteins ahead of next years’ anticipated Plasminogen launch.